Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Illumina, Inc. (ILMN : NSDQ)
 
 • Company Description   
Illumina, Inc. is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Their products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Number of Employees: 9,150

 
 • Price / Volume Information   
Yesterday's Closing Price: $233.74 Daily Weekly Monthly
20 Day Moving Average: 1,248,926 shares
Shares Outstanding: 157.10 (millions)
Market Capitalization: $36,720.55 (millions)
Beta: 0.99
52 Week High: $526.00
52 Week Low: $208.35
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.40% -23.74%
12 Week -25.08% -18.70%
Year To Date -38.56% -26.94%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5200 ILLUMINA WAY
-
SAN DIEGO,CA 92122
USA		 ph: 858-202-4500
fax: 858-202-4766		 ir@illumina.com http://www.illumina.com
 
 • General Corporate Information   
Officers
Francis A. deSouza - President and Chief Executive Officer
John W. Thompson - Chairman
Sam A. Samad - Senior Vice President and Chief Financial Officer
Jose Torres - Vice President and Chief Accounting Officer
Frances Arnold - Director

Peer Information
Illumina, Inc. (CORR.)
Illumina, Inc. (RSPI)
Illumina, Inc. (CGXP)
Illumina, Inc. (BGEN)
Illumina, Inc. (GTBP)
Illumina, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 452327109
SIC: 3826
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 157.10
Most Recent Split Date: 9.00 (2.00:1)
Beta: 0.99
Market Capitalization: $36,720.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.67 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $4.11 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 31.18% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 56.91
Trailing 12 Months: 45.47
PEG Ratio: 1.83
Price Ratios
Price/Book: 3.37
Price/Cash Flow: 31.09
Price / Sales: 7.89
EPS Growth
vs. Year Ago Period: -43.39%
vs. Previous Quarter: 42.67%
Sales Growth
vs. Year Ago Period: 11.89%
vs. Previous Quarter: 2.09%
ROE
03/31/22 - 8.37
12/31/21 - 11.35
09/30/21 - 15.03
ROA
03/31/22 - 5.78
12/31/21 - 7.48
09/30/21 - 9.52
Current Ratio
03/31/22 - 1.85
12/31/21 - 2.48
09/30/21 - 2.68
Quick Ratio
03/31/22 - 1.54
12/31/21 - 2.09
09/30/21 - 2.24
Operating Margin
03/31/22 - 16.82
12/31/21 - 19.71
09/30/21 - 22.29
Net Margin
03/31/22 - 15.04
12/31/21 - 16.82
09/30/21 - 21.17
Pre-Tax Margin
03/31/22 - 18.37
12/31/21 - 19.53
09/30/21 - 25.56
Book Value
03/31/22 - 69.35
12/31/21 - 68.71
09/30/21 - 67.77
Inventory Turnover
03/31/22 - 3.46
12/31/21 - 3.48
09/30/21 - 3.46
Debt-to-Equity
03/31/22 - 0.11
12/31/21 - 0.16
09/30/21 - 0.16
Debt-to-Capital
03/31/22 - 10.23
12/31/21 - 13.63
09/30/21 - 13.74
 

Powered by Zacks Investment Research ©